Background and aim Atrial fibrillation (AF) is the most frequently observed cardiac
arrhythmia in clinical settings. Obesity can influence the efficacy of the treatment …

Aims We conducted a systematic review and meta-analysis on three outcomes. We
assessed the efficacy and safety of direct oral anticoagulants (DOAC) compared to vitamin K …

Introduction Atrial fibrillation (AF) is the most common arrhythmia, with an estimated
prevalence between 1–4%. On the other hand, obesity continued to be a prevalent health …

The prevalence of both atrial fibrillation (AF) and obesity has steadily increased. Nonvitamin
K antagonist oral anticoagulants (NOACs) have been shown to be more effective and safer …

Purpose Oral anticoagulants are crucial for preventing systemic thromboembolism in atrial
fibrillation (AF), with guidelines preferring non-vitamin K antagonist oral anticoagulants …

Highlights•Obesity is an important risk factor for atrial fibrillation.•Despite “obesity paradox”
in atrial fibrillation, patient weight loss preferred.•Oral anticoagulants may be more …

Abstract Background and Aim Obesity affects nearly 650 million adults worldwide, and the
prevalence is steadily rising. This condition has significant adverse effects on cardiovascular …

Background The efficacy and safety of non-vitamin K-dependent anticoagulants (NOAC) are
not well investigated in the obese population, and fixed dosing could lead to under …

Background Atrial fibrillation (AF) is an irregular heart rhythm which is becoming more and
more common in this new era. Obesity is a risk factor for cardiovascular events, and obese …

Background: Direct oral anticoagulants (DOACs) have been increasingly preferred over
warfarin; however, The International Society of Thrombosis and Hemostasis recommended …